ArticleSaudi medical journal2025
GLP-1 analog therapy and hemoglobin levels: Insights from a retrospective study.
Article in Saudi medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Possible Hematological Cost of Metabolic Success: Do Incretin-Based Therapies Silently Trigger Anemia?Medical sciences (Basel, Switzerland) · 2026Review
- Micronutrient risk with GLP-1 receptor and dual incretin agonists in obesity: Mechanistic pathways, clinical signals, and a monitoring framework.Obesity pillars · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the hematological impact of Glucagon-like peptide-1 (GLP-1) analogs, specifically changes in hemoglobin and ferritin levels. Glucagon-like peptide-1 analogs, pivotal in managing type 2 diabetes mellitus (T2DM) and obesity, exhibit diverse physiological effects. While their impact on glycemic control is well-established, understanding their influence on hematological parameters remains an active area of investigation.
methodsA cohort of 700 patients prescribed GLP-1 analogs between March 2021 and October 2022 was analyzed. Demographic data, baseline hemoglobin, ferritin levels, and subsequent measurements were collected. Statistical analyses included descriptive statistics, Wilcoxon signed-rank tests, Mann-Whitney U tests, subgroup analyses, and multivariable logistic regression.
resultsFollowing GLP-1 analog initiation, a statistically significant decrease in hemoglobin levels was observed (median decrease: 0.2 g/dL), with 59 patients (8.4%) developing anemia. Ferritin levels showed no significant change. Subgroup analyses by gender and medication type revealed no significant differences in hemoglobin changes. Baseline hemoglobin demonstrated a significant inverse association with anemia development (OR=0.31, 95% CI: 0.21-0.44,
conclusionThis study contributes valuable insights into the complex interplay between GLP-1 analogs and hematological parameters. Clinicians should be aware of potential hematological effects, with baseline hemoglobin levels serving as a valuable predictor of anemia risk. Future prospective studies are warranted to deepen understanding and refine clinical strategies in the use of GLP-1 analogs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.